Sirolimus Shrinks Some Tuberous Sclerosis Tumors

Thomas N. Darling, MD, PhD Department of Dermatology Uniformed Services University of the Health Sciences Bethesda, MD 20814 Interview with:

Thomas N. Darling, MD, PhD
Department of Dermatology
Uniformed Services University of the Health Sciences
Bethesda, MD 20814

Medical Research: What is the background for this study? What are the main findings?

Dr. Darling: Many people with tuberous sclerosis complex (TSC) have skin tumors that can bleed or cause distress. Only surgical approaches were useful for treating these skin tumors in the past. Recently, drugs called mTOR inhibitors, including sirolimus, were shown to shrink internal tumors in those affected by tuberous sclerosis complex. We wanted to document what happens to the skin tumors in those being treated with oral sirolimus. We found that most patients taking oral sirolimus showed improvement in their skin tumors, and that these effects were maintained during a couple years of treatment. We did not observe any evidence for the skin tumors becoming resistant to the drug.

Medical Research: What should clinicians and patients take away from your report?

Dr. Darling: This is encouraging news to patients, since those being treated for an internal tumor can expect to see some improvement in their skin as well. However, we would not recommend oral treatment for just skin tumors due to the possibility of adverse drug effects that occur in some people.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Darling: Research is being done on the use of mTOR inhibitors applied topically to the skin rather than taking a pill. Patients show improvement in their skin without the side effects of oral treatment. This is a promising area for further research.

Another problem is that most tumors in those with TSC tend to regrow after stopping treatment. New drugs are needed that completely eradicate the tumors.


Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus

Nathan, Neera et al.

Journal of the American Academy of Dermatology

DOI: is not a forum for the exchange of personal medical information, advice or the promotion of self-destructive behavior (e.g., eating disorders, suicide). While you may freely discuss your troubles, you should not look to the Website for information or advice on such topics. Instead, we recommend that you talk in person with a trusted medical professional.

The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Thomas N. Darling, MD, PhD (2015). Sirolimus Shrinks Some Tuberous Sclerosis Tumors